Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pura Ballester, Javier Muriel & Ana M Peiró. (2022) CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia. Expert Opinion on Drug Metabolism & Toxicology 18:4, pages 261-275.
Read now
Read now
Concetta Dagostino, Massimo Allegri, Valerio Napolioni, Simona D’Agnelli, Elena Bignami, Antonio Mutti & Ron HN van Schaik. (2018) CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. Pharmacogenomics and Personalized Medicine 11, pages 179-191.
Read now
Read now
Joseph Finkelstein, Carol Friedman, George Hripcsak & Manuel Cabrera. (2016) Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmacogenomics and Personalized Medicine 9, pages 107-116.
Read now
Read now
Joseph Finkelstein, Carol Friedman, George Hripcsak & Manuel Cabrera. (2016) Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmacogenomics and Personalized Medicine 9, pages 31-45.
Read now
Read now
Joana Barbosa, Juliana Faria, Odília Queirós, Roxana Moreira, Félix Carvalho & Ricardo Jorge Dinis-Oliveira. (2016) Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metabolism Reviews 48:4, pages 577-592.
Read now
Read now
Pascal H Vuilleumier, Ulrike M Stamer & Ruth Landau. (2012) Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine 5, pages 73-87.
Read now
Read now
Articles from other publishers (7)
Huihui Liu, Jing Jing, Anxin Wang, Qin Xu, Xia Meng, Hao Li, Zixiao Li & Yongjun Wang. (2023) Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction. Neurology 100:16, pages e1643-e1654.
Crossref
Crossref
O. P. Bobrova, N. A. Shnayder, S. K. Zyryanov, Yu. A. Dyhno, M. M. Petrova & R. F. Nasyrova. (2019) Clinico-pharmacological characteristics of opioid drug-drug interactions in cancer patients with chronic pain syndrome. Siberian journal of oncology 17:6, pages 114-122.
Crossref
Crossref
Gerasimos Siasos, Vasiliki Tsigkou, Evangelos Oikonomou, Marina Zaromitidou & Dimitris Tousoulis. 2018. Coronary Artery Disease. Coronary Artery Disease
391
415
.
Marsha Tadje. (2015) Genetic Variants Influencing Patient Response to Opioid Therapy. Oncology Nursing Forum 42:4, pages 420-422.
Crossref
Crossref
K. Shankar & H.M. Mehendale. 2014. Encyclopedia of Toxicology. Encyclopedia of Toxicology
1125
1127
.
Edith Caroline Smith. (2013) Understanding CYP2D6 and Its Role in Tamoxifen Metabolism. Oncology Nursing Forum 40:6, pages 547-548.
Crossref
Crossref
Jivan Moaddeb & Susanne B. Haga. (2013) Pharmacogenetic testing: current evidence of clinical utility. Therapeutic Advances in Drug Safety 4:4, pages 155-169.
Crossref
Crossref